Following the success of ADAURA in EGFR-mutated tumours, the phase III ALINA trial evaluated 2 years of adjuvant alectinib versus standard PBC in patients with ALK-rearranged stage IB-IIIA (TNM7) resected NSCLC. Here, EGFR is linked to neoplasm.